These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 6498945)
81. The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. Coker HA; Petersen-Mahrt SK DNA Repair (Amst); 2007 Feb; 6(2):235-43. PubMed ID: 17161027 [TBL] [Abstract][Full Text] [Related]
83. Some kinetic studies on cytidine aminohydrolase activity from Aspergillus niger NRRL3. Ali TH Acta Microbiol Pol; 1998; 47(4):365-72. PubMed ID: 10333559 [TBL] [Abstract][Full Text] [Related]
84. Deoxycytidine deaminase-deficient Escherichia coli strains display acute sensitivity to cytidine, adenosine, and guanosine and increased sensitivity to a range of antibiotics, including vancomycin. Kang TM; Yuan J; Zhou A; Beppler C; Miller JH J Bacteriol; 2014 Jun; 196(11):1950-7. PubMed ID: 24633874 [TBL] [Abstract][Full Text] [Related]
85. Dispelling the effects of a sorceress in enzyme catalysis. Mulholland AJ Proc Natl Acad Sci U S A; 2016 Mar; 113(9):2328-30. PubMed ID: 26884176 [No Abstract] [Full Text] [Related]
86. Correction to: The cytidine deaminase under-representation reporter (CDUR) as a tool to study evolution of sequences under deaminase mutational pressure. Shapiro M; Meier S; MacCarthy T BMC Bioinformatics; 2018 Jul; 19(1):256. PubMed ID: 29973133 [TBL] [Abstract][Full Text] [Related]
87. Identification of a specific domain required for dimerization of activation-induced cytidine deaminase. Wang J; Shinkura R; Muramatsu M; Nagaoka H; Kinoshita K; Honjo T J Biol Chem; 2008 Jan; 283(1):660. PubMed ID: 18210667 [No Abstract] [Full Text] [Related]
88. Author Correction: Cytidine deaminase activity increases in the blood of breast cancer patients. Buhagiar-Labarchède G; Onclercq-Delic R; Vacher S; Berger F; Bièche I; Stoppa-Lyonnet D; Amor-Guéret M Sci Rep; 2022 Dec; 12(1):21002. PubMed ID: 36470892 [No Abstract] [Full Text] [Related]
90. The measurement of nucleoside deaminases by high performance liquid chromatography and their use in clinical chemistry. Sherwood RA Biomed Chromatogr; 1991 Nov; 5(6):235-9. PubMed ID: 1760590 [TBL] [Abstract][Full Text] [Related]
91. Synergistic toxicity of pyrazofurin and cytidine in cytidine deaminase deficient lymphoid cells (Raji). Pérignon JL; Thuillier L; Hamet M; Houllier AM; Cartier PH Int J Immunopharmacol; 1986; 8(4):427-31. PubMed ID: 3744641 [TBL] [Abstract][Full Text] [Related]
92. Low cytidine deaminase levels in human hematopoietic cell lines. Nygaard P; Sundström C Leuk Res; 1987; 11(8):681-5. PubMed ID: 3626611 [TBL] [Abstract][Full Text] [Related]
93. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells. Mejer JN; Mortensen BT; Christensen IJ Med Oncol Tumor Pharmacother; 1990; 7(1):25-9. PubMed ID: 2338846 [TBL] [Abstract][Full Text] [Related]
94. Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase. Mejer J; Mortensen BT Adv Exp Med Biol; 1989; 253B():335-9. PubMed ID: 2558539 [No Abstract] [Full Text] [Related]
95. Cytidine deaminase levels in cultured mammalian cell lines measured by the growth tests and enzyme assays. Ishii K; Sakamoto H; Furuyama J; Hanaoka M Cell Struct Funct; 1984 Jun; 9(2):117-23. PubMed ID: 6498945 [TBL] [Abstract][Full Text] [Related]